Skip to main content
Premium Trial:

Request an Annual Quote

DOE Gives Genelabs $4.8M For Pathogens Research

Premium

REDWOOD CITY, Calif.--Biopharmacauetical company Genelabs Technologies will receive $4.8 million to fund its second year of genomics-based research for the US Defense Advanced Research Projects Agency, the research arm of the US Department of Defense. The funding is a 25 percent increase over what Genelabs received in 1998 under the agency's Unconventional Pathogen Countermeasures Program. Genelabs will use the money to apply its platform technologies, which create drugs that function by binding to DNA or double-stranded RNA, to develop pharmaceutical countermeasures to biological warfare agents.

Filed under

The Scan

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.